Seattle Genetics, Astellas win FDA approval for bladder cancer drug – MedCity News

The FDA approved Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma, which marks the Seattle biotech’s second regulatory approval.

Read the full article here

Related Articles